Comparative Pharmacology
Head-to-head clinical analysis: KAFOCIN versus ZEVTERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAFOCIN versus ZEVTERA.
KAFOCIN vs ZEVTERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Ceftobiprole, the active moiety of ZEVTERA, is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in methicillin-resistant Staphylococcus aureus (MRSA), leading to cell death.
1 g IV every 8 hours.
400 mg intravenously every 8 hours
None Documented
None Documented
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
Terminal elimination half-life is approximately 3.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to ~6 hours, requiring dose adjustment.
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Approximately 70% of the dose is excreted unchanged in urine, with 20% recovered in feces via biliary elimination. Minor route: <5% as metabolites.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic